



Section: 6. Anti-infective medicines > 6.5. Antiprotozoal medicines > 6.5.5. Antitrypanosomal medicines > 6.5.5.1. African trypanosomiasis > 6.5.5.1.1. Medicines for the treatment of 1st stage African trypanosomiasis

EMLc

ATC codes: P01CX02

<b>Indication</b>	African trypanosomiasis	ICD11 code: <b>1F51</b>
<b>INN</b>	Suramin sodium	
<b>Medicine type</b>	Chemical agent	
<b>List type</b>	Core (EML) (EMLc)	
<b>Additional notes</b>	To be used for the treatment of the initial phase of <i>Trypanosoma brucei rhodesiense</i> infection.	
<b>Formulations</b>	Parenteral > General injections > IV: 1 g in vial	
<b>EML status history</b>	First added in 1977 (TRS 615) Changed in 1979 (TRS 641) Changed in 2007 (TRS 946) Changed in 2007 (TRS 950)	
<b>Sex</b>	All	
<b>Age</b>	Also recommended for children	
<b>Therapeutic alternatives</b>	The recommendation is for this specific medicine	
<b>Patent information</b>	Patents have expired in most jurisdictions Read more <a href="#">about patents</a> .	
<b>Wikipedia</b>	<a href="#">Suramin sodium</a>	
<b>DrugBank</b>	<a href="#">Suramin sodium (Suramin)</a>	

### Summary of evidence and Expert Committee recommendations

The EMLc Subcommittee recommended that suramin sodium be endorsed for the EMLc for treatment of first-stage of *Trypanosoma brucei rhodesiense* infections. The Subcommittee noted that African trypanosomiasis is a major public health problem in affected countries. Medicines available for treating this infection are limited. Hence despite the toxicity profile, these medicines are still used. There is a paucity of documented information specific to children and recommendations for adults are usually followed.

